Literature DB >> 8995691

Expression and maturation of human foamy virus Gag precursor polypeptides.

M L Giron1, S Colas, J Wybier, F Rozain, R Emanoil-Ravier.   

Abstract

In this report, we address the processing of the Gag polypeptides of human foamy virus previously reported to be atypical. In the cytoplasm or the nucleus of infected cells as well as in free virus particles, two Gag precursor polypeptides were identified at approximately 72 and 68 kDa, p72 giving rise to p68 by a maturation process. Efficient maturation of Gag precursors was observed only in two situations: (i) during the early steps of virus adsorption and (ii) under experimental conditions, including treatment with DNase I, known to dissociate actin polymers associated with high ionic strength and ionic detergents. Rather than being a defective viral protease function, an association of Gag precursors with a cytoskeleton network might be responsible for the low rate of Gag protein maturation through inhibition of their cleavage by the protease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8995691      PMCID: PMC191222     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

1.  Analysis of splicing patterns of human spumaretrovirus by polymerase chain reaction reveals complex RNA structures.

Authors:  W Muranyi; R M Flügel
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

2.  Cleavage of human and mouse cytoskeletal and sarcomeric proteins by human immunodeficiency virus type 1 protease. Actin, desmin, myosin, and tropomyosin.

Authors:  R L Shoeman; C Sachse; B Höner; E Mothes; M Kaufmann; P Traub
Journal:  Am J Pathol       Date:  1993-01       Impact factor: 4.307

3.  Human foamy virus genome possesses an internal, Bel-1-dependent and functional promoter.

Authors:  M Löchelt; W Muranyi; R M Flügel
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-01       Impact factor: 11.205

4.  Endonucleolytic cleavages and DNA-joining activities of the integration protein of human foamy virus.

Authors:  A Pahl; R M Flügel
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

5.  Identification of pol-related gene products of human foamy virus.

Authors:  K O Netzer; A Schliephake; B Maurer; R Watanabe; A Aguzzi; A Rethwilm
Journal:  Virology       Date:  1993-01       Impact factor: 3.616

6.  Human foamy virus proteins accumulate in neurons and induce multinucleated giant cells in the brain of transgenic mice.

Authors:  A Aguzzi; E F Wagner; K O Netzer; K Bothe; I Anhauser; A Rethwilm
Journal:  Am J Pathol       Date:  1993-04       Impact factor: 4.307

7.  Functional dissection of the human spumaretrovirus transactivator identifies distinct classes of dominant-negative mutants.

Authors:  L K Venkatesh; C Yang; P A Theodorakis; G Chinnadurai
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

8.  Human foamy virus polypeptides: identification of env and bel gene products.

Authors:  M L Giron; F Rozain; M C Debons-Guillemin; M Canivet; J Peries; R Emanoil-Ravier
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

9.  Bacterial expression of the capsid antigen domain and identification of native gag proteins in spumavirus-infected cells.

Authors:  A Bartholomä; W Muranyi; R M Flügel
Journal:  Virus Res       Date:  1992-04       Impact factor: 3.303

10.  A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells.

Authors:  M I Bukrinsky; S Haggerty; M P Dempsey; N Sharova; A Adzhubel; L Spitz; P Lewis; D Goldfarb; M Emerman; M Stevenson
Journal:  Nature       Date:  1993-10-14       Impact factor: 69.504

View more
  28 in total

1.  Protease-dependent uncoating of a complex retrovirus.

Authors:  Jacqueline Lehmann-Che; Marie-Lou Giron; Olivier Delelis; Martin Löchelt; Patricia Bittoun; Joelle Tobaly-Tapiero; Hugues de Thé; Ali Saïb
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

2.  Basic residues in the foamy virus Gag protein.

Authors:  Daniel Matthes; Tatiana Wiktorowicz; Juliane Zahn; Jochen Bodem; Nicole Stanke; Dirk Lindemann; Axel Rethwilm
Journal:  J Virol       Date:  2011-02-02       Impact factor: 5.103

3.  Carboxy-terminal cleavage of the human foamy virus Gag precursor molecule is an essential step in the viral life cycle.

Authors:  J Enssle; N Fischer; A Moebes; B Mauer; U Smola; A Rethwilm
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

4.  Identification of a conserved residue of foamy virus Gag required for intracellular capsid assembly.

Authors:  S W Eastman; M L Linial
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

5.  PML mediates the interferon-induced antiviral state against a complex retrovirus via its association with the viral transactivator.

Authors:  T Regad; A Saib; V Lallemand-Breitenbach; P P Pandolfi; H de Thé; M K Chelbi-Alix
Journal:  EMBO J       Date:  2001-07-02       Impact factor: 11.598

6.  Mutations in the amino terminus of foamy virus Gag disrupt morphology and infectivity but do not target assembly.

Authors:  Rachel B Life; Eun-Gyung Lee; Scott W Eastman; Maxine L Linial
Journal:  J Virol       Date:  2008-04-23       Impact factor: 5.103

Review 7.  Foamy viruses are unconventional retroviruses.

Authors:  M L Linial
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

8.  Intra- and intercellular trafficking of the foamy virus auxiliary bet protein.

Authors:  Charles-Henri Lecellier; Wim Vermeulen; Françoise Bachelerie; Marie-Lou Giron; Ali Saïb
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

9.  Evidence that the human foamy virus genome is DNA.

Authors:  S F Yu; M D Sullivan; M L Linial
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

10.  Further characterization of equine foamy virus reveals unusual features among the foamy viruses.

Authors:  Charles-Henri Lecellier; Manuel Neves; Marie-Lou Giron; Joelle Tobaly-Tapiero; Ali Saïb
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.